SCHEMBL321617

SCHEMBL321617

C=CCn1c(C)c(C(=O)OCC)c(=O)c2cc(C(=O)c3c(C)c(OC)c4ccccn34)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.46
▸ MAPT P10636 4/20 0.39
▸ KDM4E B2RXH2 6/20 0.38
▸ ALDH1A1 P00352 6/20 0.38
▸ HPGD P15428 3/20 0.38
▸ TSHR P16473 3/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ PTGER4 P35408 1/20 0.37
▸ GAA P10253 2/20 0.36
▸ PKM P14618 1/20 0.36
▸ HCRTR1 O43613 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ FNTA P49354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14916473 0.82 CDYL2 (0.38) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL321028 0.79 HCRTR1 (0.44) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL321051 0.78 ALDH1A1 (0.44) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL320650 0.76 HTT (0.38) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL10084838 0.75 LMNA (0.55) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL321292 0.74 ALDH1A1 (0.52) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL320775 0.71 POLB (0.41) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL321473 0.70 HTT (0.41) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL17004134 0.70 HTT (0.39) LMNAMAPTKDM4EALDH1A1HTT
SCHEMBL320822 0.69 ALDH1A1 (0.37) LMNAMAPTKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 — — EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 LMNA 738/4885MAPT 961/4885KDM4E 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback